Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Subscribe To Our Newsletter & Stay Updated
